Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Post by general360on Apr 29, 2021 2:26pm
231 Views
Post# 33094689

ded-$

ded-$
completely dead money....recent PP announced via agoracommie - thanku koo - 4/26 for 150k.  sounds like enuf to pay the staff for maybe another month or so.... im not sure, i might go out on a limb, but i'll guess - dont kill the messenger - that this might slip into may.  hate to say it!

so we'll sit, like i said, here we come 3 MONTHS since "IMMEDIATE FILING".....

with pfizer announcing magic pill by end of the year, we have to view them as an enemy/competitor.  are we being strung along by them?   looks like full steam ahead for them with their pill.  id totally be guessing, but how much will it cost them to move this from p1 through p2a/b, will they have to do a p3 too? before they get emergency use auth?  a few hundres million?  instead of the billions we're "hoping" for our p2 failed p3 wunderbar?

who else will step up and eat our lunch?
<< Previous
Bullboard Posts
Next >>